27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Nutrition is known to modulate the immune system and may alter neuroinflammatory processes implicated in the pathogenesis of Alzheimer's disease (AD) and progression of neurodegeneration. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
In this paper, we conduct a literature survey on various virtual reality (VR) treatments in psychiatry. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Reducing participant burden, while ensuring that technological tools are suitable for older individuals, maintaining face-to-face contacts, and taking into account participant characteristics may increase adherence in future trials. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Individualized multidomain interventions may improve cognition and reduce AD/cardiovascular risk scores in patients at-risk for AD dementia. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Dementia directly influences the quality of life of a person suffering from this chronic illness. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Down syndrome (DS) has been proposed by George Martin as a segmental progeroid syndrome since 1978. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The risk of Alzheimer's disease (AD) increases with nonmodifiable conditions including age and lack of effective efficacious pharmacotherapy. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
It has been shown that aromatherapy with essential oils from the mint family can improve cognitive performance in Alzheimer's disease patients. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Nowadays, Alzheimer's disease (AD) is a severe sociological and clinical problem. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The prevalence of degenerative diseases has risen in western countries. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Neuroinflammation is a common feature shared by neurodegenerative disorders, such as Parkinson's disease (PD), and seems to play a key role in their development and progression. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
These results are especially relevant when compared to previous SSD studies showing effects in behavior only after a demanding cognitive training. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) is a neurodegenerative disease and the leading cause of dementia worldwide. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Our in vivo model of c9FTD/ALS is the first to robustly recapitulate hallmark features derived from both sense and antisense C9orf72 repeat-associated transcripts complete with neurodegeneration and behavioral impairments. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
A standardized assessment battery that captures shared characteristics of mobility and cognition seen in aging and neurodegeneration may increase comparability across research studies, detection of subtle or common reversible factors, and accelerate research progress in dementia, falls, and aging-related disabilities. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Drugs with anticholinergic action are widely prescribed in the elderly population due to their potential clinical benefits. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Vitamin E was proposed as treatment for Alzheimer's disease many years ago. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Various methods of rehabilitation for dysphagia have been suggested through the experience of treating stroke patients. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The fundamental role that alpha-synuclein (aSyn) plays in the pathogenesis of neurodegenerative synucleinopathies, including Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy, is a well-accepted fact. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The process of advance care planning in dementia is far from straightforward; as dementia progresses, the ability to consider future thoughts and actions becomes compromised, thus affecting decision-making abilities. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Ageing is an inevitable fundamental process for people and is their greatest risk factor for neurodegenerative disease. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Study results emphasize the need for improved EOL counseling in DLB, recognition of EOL symptoms, earlier hospice involvement, tailoring EOL care to DLB-specific needs, and clinician-family communication. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Although a high proportion of patients received elements of palliative care, transitions to a goal of comfort or hospice happened very near death. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Evaluation of each patient using a variety of decision making tools should help the orthopedic surgeon determine which patients would be better suited to non-operative management. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The geriatrician can have an important role in decisions for non-surgical management by shared decision making in the pre-operative period in patients ≥ 70 years with a hip fracture in the emergency room. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →